SEC Filing Madrigal Pharmaceuticals.

$ 12.50

4.8 (771) In stock

Madrigal Pharmaceuticals Inc - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of

Madrigal Pharmaceuticals (MDGL) 10K Form and SEC Filings 2024

g468630.jpg

MDGL - Madrigal Pharmaceuticals Provides Corporate Updates and Reports 2022 Fourth Quarter and Full Year Financial Results

SEC Filing NeuroBo Pharmaceuticals, Inc.

Madrigal Pharmaceuticals Inc - DEF 14A - Proxy Statement - May 01, 2023

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

Latest Pharma News - Biogen, Sanofi, Bristol, UCB, Eli Lilly, and Pharming

Overview Madrigal Pharmaceuticals.

MDGL / Madrigal Pharmaceuticals, Inc. - Put/Call Ratio, Options Sentiment, Unusual Options Activity

SEC Filing

American Century Companies Inc. Increases Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

SEC Filing

Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play (NASDAQ:MDGL)

SEC Filing